Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 258

    1.

    Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

    Chang DZ, Kumar V, Ma Y, Li K, Kopetz S.

    J Hematol Oncol. 2009 Apr 22;2:18. Review.

    PMID:
    19386128
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

    Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

    J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. Epub 2009 Sep 8. Review.

    PMID:
    19738166
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

    Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

    J Clin Oncol. 2010 Nov 1;28(31):4769-77. Epub 2010 Oct 4. Review.

    PMID:
    20921461
    [PubMed - indexed for MEDLINE]
    4.

    Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

    Ann Surg. 2010 Feb;251(2):254-60.

    PMID:
    20010090
    [PubMed - indexed for MEDLINE]
    5.

    Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

    J Clin Oncol. 2009 Dec 10;27(35):5924-30. Epub 2009 Nov 2.

    PMID:
    19884556
    [PubMed - indexed for MEDLINE]
    6.

    Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

    Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S.

    Target Oncol. 2010 Mar;5(1):19-28. Epub 2010 Apr 11. Review.

    PMID:
    20383783
    [PubMed - indexed for MEDLINE]
    7.

    KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.

    Baynes RD, Gansert J.

    Am J Ther. 2009 Nov-Dec;16(6):554-61. Review.

    PMID:
    19352138
    [PubMed - indexed for MEDLINE]
    8.

    The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

    Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T.

    Dtsch Arztebl Int. 2009 Mar;106(12):202-6. Epub 2009 Mar 20. Review.

    PMID:
    19471640
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

    Ciardiello F, Tejpar S, Papamichael D.

    Target Oncol. 2009 Dec;4(4):311-22. Epub 2009 Nov 14.

    PMID:
    19915942
    [PubMed - indexed for MEDLINE]
    10.

    Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

    J Clin Oncol. 2008 Dec 10;26(35):5705-12. Epub 2008 Nov 10.

    PMID:
    19001320
    [PubMed - indexed for MEDLINE]
    11.

    Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

    Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A.

    Pathol Res Pract. 2009;205(12):858-62. Epub 2009 Aug 12.

    PMID:
    19679400
    [PubMed - indexed for MEDLINE]
    12.

    KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

    Siddiqui AD, Piperdi B.

    Ann Surg Oncol. 2010 Apr;17(4):1168-76. Epub 2009 Nov 20. Review.

    PMID:
    19936839
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

    Mancl EE, Kolesar JM, Vermeulen LC.

    Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. Review.

    PMID:
    19923311
    [PubMed - indexed for MEDLINE]
    14.

    The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.

    Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F.

    Oncology. 2009;77 Suppl 1:57-68. Epub 2010 Feb 2. Review.

    PMID:
    20130433
    [PubMed - indexed for MEDLINE]
    16.

    KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

    van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A.

    Virchows Arch. 2008 Nov;453(5):417-31. Epub 2008 Sep 18. Review. Erratum in: Virchows Arch. 2009 Feb;454(2):233-5.

    PMID:
    18802721
    [PubMed - indexed for MEDLINE]
    17.

    KRAS mutation testing in colorectal cancer.

    Plesec TP, Hunt JL.

    Adv Anat Pathol. 2009 Jul;16(4):196-203. Review.

    PMID:
    19546608
    [PubMed - indexed for MEDLINE]
    18.

    Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

    Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F.

    Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. Epub 2009 Jul 28. Review.

    PMID:
    19636327
    [PubMed - indexed for MEDLINE]
    19.

    Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

    Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

    Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. Review.

    PMID:
    21129611
    [PubMed - indexed for MEDLINE]
    20.

    Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

    Ruzzo A, Graziano F, Canestrari E, Magnani M.

    Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

    PMID:
    20088793
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk